The historical rank and industry rank for Mirum Pharmaceuticals's Net Margin % or its related term are showing as below:
STU:08D'
s Net Margin % Range Over the Past 10 Years
Min: -438.85 Med: -87.68 Max: -4.48
Current: -140.24
STU:08D's Net Margin % is ranked worse than 54.8% of 947
companies
in the Biotechnology industry
Industry Median: -89.56
vs STU:08D: -140.24
Mirum Pharmaceuticals (STU:08D) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Mirum Pharmaceuticals Net Margin % Related Terms
Mirum Pharmaceuticals Net Margin % Historical Data
* Premium members only.
The historical data trend for Mirum Pharmaceuticals's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:08D vs APGE, PTCT, RYTM: Net Margin % Comparison
For the Biotechnology subindustry, Mirum Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mirum Pharmaceuticals Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Mirum Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirum Pharmaceuticals (STU:08D) has a Net Margin % of -494.21% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Mirum Pharmaceuticals and its competitors. According to the industry distribution chart, Mirum Pharmaceuticals ranks #519 out of 947 companies in the Biotechnology industry, placing it in the top 54.8%.
Is Mirum Pharmaceuticals' Net Margin % too high?
Mirum Pharmaceuticals' current Net Margin % is -494.21%. Based on the distribution chart, Mirum Pharmaceuticals ranks #519 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Mirum Pharmaceuticals has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Net Margin % compare to APGE and PTCT?
According to the Biotechnology industry distribution chart, Mirum Pharmaceuticals ranks #519 out of 947 companies for Net Margin %. This places Mirum Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current Net Margin % is -494.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mirum Pharmaceuticals (STU:08D) is currently considered Significantly Overvalued. The stock's GF Value™ is €72.26, compared to a current price of €97.60 — trading 35.1% above its estimated fair value. The current Net Margin % is -494.21%. Mirum Pharmaceuticals' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Mirum Pharmaceuticals (STU:08D), the current Net Margin % is -494.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mirum Pharmaceuticals (STU:08D) Overvalued in 2026?
Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued.
The current stock price of €97.60 is trading 35.1% above its estimated GF Value™ of €72.26.
GuruFocus considers Mirum Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for STU:08D:
Net Margin %: -494.21%
GF Value™: €72.26 vs. price of €97.60 (35.1% above fair value)
No single metric tells the full story. See the STU:08D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
47GF Score
Get the complete analysis for STU:08D
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:08D has been successfully added to your 
